Table 1. Hemophiliac LTNPs and... | American Society of Hematology

Table 1.

Hemophiliac LTNPs and Progressors

Patient No.	Age (yr)/Sex	Hemophilia Type	1st Anti-HIV⁺ (yr)	CD4⁺ Count (cells/μL)^*	CD8⁺ Count (cells/μL)^*	CDC Group	Start Anti-HIV Therapy (yr)	HLA Type
								Class I	Class II
LTNPs

1	20/M	B	1984	1,135	1,841			A11, 30; B14, 38	DR10
								Cw6; Bw4, 6	DQ1
2	33/M	A	1983	600	1,607			A2, 32; B35, 51	DR11, 14, 52
								Cw3, 4; Bw4, 6	DQ1, 7
3	29/M	A	1984	1,047	1,806			A3, 11; B13, 35	DR1, 7, 53
								Cw6; Bw4, 6	DQ1, 2
4	18/F	B carrier	1984	905	988			A1; B51, 57	DR4, 52, 53
								Cw1, 6; Bw4	DQ1, 3
5	46/M	B	1985	619	1,164			A2; B50, 57	DR1, 3, 52
								Cw6; Bw4, 6	DQ1, 2
6	18/M	A	1985	630	680			A3, 33; B13, 14	DR1, 7, 53
								Cw6; Bw4, 6	DQ1, 2
7	26/M	A	1983	669	1,155			A3, 11; B44, 51	DR7
								Bw4	DQ2
Progressors

8	42/M	A	1984	445^†	1,886	A2	NA	A2, 26; B35, 57	DR2, 11, 52
								Cw4; Bw4, 6	DQ1, 7
9	36/M	A	1984	162	1,002	C2	1991	A25, 28; B18, 35	DR4, 15, 53
								Cw3, 4; Bw4, 6	DQ1, 3
10	27/M	A	1985	105	603	B2	1993	A1, 2; B35, 49	DR1, 7, 53
								Cw4, 7; Bw4, 6	DQ1, 2
11	22/M	A	1983	139	1,201	C2	1992	A2, 26; B35, 51	DR1, 13, 52
								Cw2, 4; Bw4, 6	DQ5
12	49/M	A	1984	122	1,314	A2	1992	A28, 34; B8, 14	DR1, 3, 52
								Cw7; Bw6	DQ1, 2
13	35/M	A	1983	56	479	B2	1993	A24, 29; B7, 44	DR3, 7, 52, 53
								Cw6, 7; Bw4, 6	DQ1, 2
14	33/M	B	1983	69	712	A2	NA	A24, 32; B62	DR12, 52
								Cw1, 7; Bw4, 6	DQ1, 7
15	35/M	B	1983	31	459	B2	NA	A3, 33; B14	DR1, 52
								Cw7; Bw6	DQ1, 3

Patient No.	Age (yr)/Sex	Hemophilia Type	1st Anti-HIV⁺ (yr)	CD4⁺ Count (cells/μL)^*	CD8⁺ Count (cells/μL)^*	CDC Group	Start Anti-HIV Therapy (yr)	HLA Type
								Class I	Class II
LTNPs

1	20/M	B	1984	1,135	1,841			A11, 30; B14, 38	DR10
								Cw6; Bw4, 6	DQ1
2	33/M	A	1983	600	1,607			A2, 32; B35, 51	DR11, 14, 52
								Cw3, 4; Bw4, 6	DQ1, 7
3	29/M	A	1984	1,047	1,806			A3, 11; B13, 35	DR1, 7, 53
								Cw6; Bw4, 6	DQ1, 2
4	18/F	B carrier	1984	905	988			A1; B51, 57	DR4, 52, 53
								Cw1, 6; Bw4	DQ1, 3
5	46/M	B	1985	619	1,164			A2; B50, 57	DR1, 3, 52
								Cw6; Bw4, 6	DQ1, 2
6	18/M	A	1985	630	680			A3, 33; B13, 14	DR1, 7, 53
								Cw6; Bw4, 6	DQ1, 2
7	26/M	A	1983	669	1,155			A3, 11; B44, 51	DR7
								Bw4	DQ2
Progressors

8	42/M	A	1984	445^†	1,886	A2	NA	A2, 26; B35, 57	DR2, 11, 52
								Cw4; Bw4, 6	DQ1, 7
9	36/M	A	1984	162	1,002	C2	1991	A25, 28; B18, 35	DR4, 15, 53
								Cw3, 4; Bw4, 6	DQ1, 3
10	27/M	A	1985	105	603	B2	1993	A1, 2; B35, 49	DR1, 7, 53
								Cw4, 7; Bw4, 6	DQ1, 2
11	22/M	A	1983	139	1,201	C2	1992	A2, 26; B35, 51	DR1, 13, 52
								Cw2, 4; Bw4, 6	DQ5
12	49/M	A	1984	122	1,314	A2	1992	A28, 34; B8, 14	DR1, 3, 52
								Cw7; Bw6	DQ1, 2
13	35/M	A	1983	56	479	B2	1993	A24, 29; B7, 44	DR3, 7, 52, 53
								Cw6, 7; Bw4, 6	DQ1, 2
14	33/M	B	1983	69	712	A2	NA	A24, 32; B62	DR12, 52
								Cw1, 7; Bw4, 6	DQ1, 7
15	35/M	B	1983	31	459	B2	NA	A3, 33; B14	DR1, 52
								Cw7; Bw6	DQ1, 3

Abbreviation: NA, not applicable.

At study entry.

CD4 cell counts of patient no. 8 decreased to 350/μL shortly after beginning the study.